AIM: The aim was to investigate the efficacy and safety of intravenous retosiban in women with spontaneous preterm labour. METHODS: This was a randomized, double-blind, placebo-controlled, phase 2 trial. Retosiban was administered intravenously for 48 h to women in spontaneous preterm labour between 30(0/7) and 35(6/7) weeks' gestation with an uncomplicated singleton pregnancy in an in-patient obstetric unit. Outcome measures were uterine quiescence (primary endpoint), days to delivery, preterm delivery and safety. RESULTS:Uterine quiescence was achieved in 62% of women who received retosiban (n = 30) compared with 41% who received placebo (n = 34). The relative risk (RR) was 1.53 (95% credible interval [CrI] 0.98, 2.48; NS). Retosiban resulted in a significant increase in time to delivery compared with placebo (mean difference 8.2 days, 95% CrI 2.7, 13.74). This difference was consistent across all gestational ages. The proportion of preterm births in the retosiban and placebo groups was 18.7% (95% CrI 7.4%, 33.7%) and 47.2% (95% CrI 31.4%, 63.4%), respectively. The RR of preterm birth in women treated with retosiban was 0.38 (95% CrI 0.15, 0.81). There were no deliveries within 7 days in the retosiban group, but there were six (17.6%) births in the placebo group. The maternal, fetal and neonatal adverse events were comparable in the retosiban and placebo groups. CONCLUSIONS: Intravenous administration of retosiban in women with spontaneous preterm labour was associated with a greater than 1 week increase in time to delivery compared with placebo, a significant reduction in preterm deliveries, a non-significant increase in uterine quiescence and a favourable safety profile.
RCT Entities:
AIM: The aim was to investigate the efficacy and safety of intravenous retosiban in women with spontaneous preterm labour. METHODS: This was a randomized, double-blind, placebo-controlled, phase 2 trial. Retosiban was administered intravenously for 48 h to women in spontaneous preterm labour between 30(0/7) and 35(6/7) weeks' gestation with an uncomplicated singleton pregnancy in an in-patient obstetric unit. Outcome measures were uterine quiescence (primary endpoint), days to delivery, preterm delivery and safety. RESULTS: Uterine quiescence was achieved in 62% of women who received retosiban (n = 30) compared with 41% who received placebo (n = 34). The relative risk (RR) was 1.53 (95% credible interval [CrI] 0.98, 2.48; NS). Retosiban resulted in a significant increase in time to delivery compared with placebo (mean difference 8.2 days, 95% CrI 2.7, 13.74). This difference was consistent across all gestational ages. The proportion of preterm births in the retosiban and placebo groups was 18.7% (95% CrI 7.4%, 33.7%) and 47.2% (95% CrI 31.4%, 63.4%), respectively. The RR of preterm birth in women treated with retosiban was 0.38 (95% CrI 0.15, 0.81). There were no deliveries within 7 days in the retosiban group, but there were six (17.6%) births in the placebo group. The maternal, fetal and neonatal adverse events were comparable in the retosiban and placebo groups. CONCLUSIONS: Intravenous administration of retosiban in women with spontaneous preterm labour was associated with a greater than 1 week increase in time to delivery compared with placebo, a significant reduction in preterm deliveries, a non-significant increase in uterine quiescence and a favourable safety profile.
Authors: David M Haas; Thomas F Imperiale; Page R Kirkpatrick; Robert W Klein; Terrell W Zollinger; Alan M Golichowski Journal: Obstet Gynecol Date: 2009-03 Impact factor: 7.661
Authors: Carolien Roos; Marc E A Spaanderman; Ewoud Schuit; Kitty W M Bloemenkamp; Antoinette C Bolte; Jérôme Cornette; Johannes J J Duvekot; Jim van Eyck; Maureen T M Franssen; Christianne J de Groot; Joke H Kok; Anneke Kwee; Ashley Merién; Bas Nij Bijvank; Brent C Opmeer; Martijn A Oudijk; Mariëlle G van Pampus; Dimitri N M Papatsonis; Martina M Porath; Hubertina C J Scheepers; Sicco A Scherjon; Krystyna M Sollie; Sylvia M C Vijgen; Christine Willekes; Ben Willem J Mol; Joris A M van der Post; Fred K Lotgering Journal: JAMA Date: 2013-01-02 Impact factor: 56.272
Authors: T M Goodwin; R Paul; H Silver; W Spellacy; M Parsons; R Chez; R Hayashi; G Valenzuela; G W Creasy; R Merriman Journal: Am J Obstet Gynecol Date: 1994-02 Impact factor: 8.661
Authors: Amie Wilson; Victoria A Hodgetts-Morton; Ella J Marson; Alexandra D Markland; Eva Larkai; Argyro Papadopoulou; Arri Coomarasamy; Aurelio Tobias; Doris Chou; Olufemi T Oladapo; Malcolm J Price; Katie Morris; Ioannis D Gallos Journal: Cochrane Database Syst Rev Date: 2022-08-10
Authors: Steven Thornton; Guillermo Valenzuela; Charlotte Baidoo; Michael J Fossler; Timothy H Montague; Linda Clayton; Marcy Powell; Jerry Snidow; Brendt Stier; David Soergel Journal: Br J Clin Pharmacol Date: 2017-07-11 Impact factor: 4.335
Authors: Irving L M H Aye; Alexandros A Moraitis; Dinesh Stanislaus; D Stephen Charnock-Jones; Gordon C S Smith Journal: J Clin Endocrinol Metab Date: 2018-03-01 Impact factor: 5.958